Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

Tinea Pedis Clinical Trial

Official title:

A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02842021
• Other study ID #: SGT-26-01
• Status: Terminated
• Phase: Phase 2
• Start date: September 2016
• Est. completion date: October 2017

Study information

• Verified date: November 2020
• Source: Sol-Gel Technologies, Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of age and older. The results of this study will be utilized to perform power calculations for the Phase 3 pivotal trials.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 283
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Ability and willingness to sign a written informed consent and /or assent (age appropriate).

2. Male or Female subjects 12 years of age or older.

3. A clinical diagnosis of interdigital tinea pedis on one or both feet characterized by clinical evidence of a tinea infection.

4. A sum of at least five (5) for signs (erythema and scaling) by the investigator on the selected target foot, and a score of at least five (5) for each symptom: pruritus (itching) and burning: and a sum of at least twelve (12) for both symptoms (pruritus and burning) by the subject on the PATSS.

5. Mycological evidence of the presence of fungi confirmed by the detection of fungal hyphae on a microscopic KOH wet mount.

6. Females of child-bearing potential must have a negative urine pregnancy test and must agree to use an effective form of contraception during the study .

7. Must be in good general health as determined by medical history and free of any disease that in the investigator's opinion might interfere with the study evaluations.

8. Must be able to communicate, be able to understand the study procedures, and be willing to comply with the study requirements.

Exclusion Criteria:

1. The presence of confluent diffuse moccasin-type tinea pedis.

2. Negative KOH microscopy test to assess presence of hyphae.

3. Onychomycosis of the toenails, involving = 20% of the area of either great toenail or involvement of more than five toenails in total.

4. Concurrent tinea infection or bacterial skin infection on the feet.

5. Female subjects who are pregnant and/or nursing or planning a pregnancy during the course of the trial.

6. Recent history of or currently known to abuse drugs or alcohol.

7. History of intolerance or hypersensitivity to Econazole Nitrate, Mometasone Furoate, or other imidazole agents.

8. Presence of any other infection of the foot or other disease process that might confound the treatment evaluation.

9. Having a life-threatening condition or immunocompromised (e.g., autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.

10. Unable to communicate or cooperate with the investigator due to language barriers, poor mental development, or impaired cerebral function.

11. Current participation in a clinical drug research study or recent participation in a clinical trial within 30 days of Baseline.

12. Using the following medications prior to Baseline:

1. Antipruritics, including antihistamines within 3 days (72 hours).

2. Topical corticosteroids, antibiotics or antifungal therapies within 4 weeks.

3. Systemic corticosteroids, antibiotics or antifungal therapies within 12 weeks.

4. Oral terbinafine or itraconazole within 12 weeks.

5. Immunosuppressive medication or radiation therapy within 12 weeks.

6. Any other topical medicated topical treatments to the treatment area(s) within 7 days.

-

Related Conditions & MeSH terms

• Tinea
• Tinea Pedis

Intervention

Drug:
• S2G6T-1
Twice a day topical cream
• S2G6T-2
Twice a day topical cream
• S2G6T-3
Twice a day topical cream
• S2G6T-4
Twice a day topical cream

Locations

Country	Name	City	State
United States	Academic Dermatology Associates	Albuquerque	New Mexico
United States	DermResearch, Inc.	Austin	Texas
United States	Mid Atlantic Research for Health	Baltimore	Maryland
United States	Tampa Bay Medical Research	Clearwater	Florida
United States	J&S Studies, Inc	College Station	Texas
United States	Minnesota Clinical Study Center	Fridley	Minnesota
United States	Suzanne Bruce & Associates, PA / The Center for Skin Research	Houston	Texas
United States	Suzanne Bruce & Associates ,PA / The Center for Skin Research	Katy	Texas
United States	The Education & Research Foundation Inc.	Lynchburg	Virginia
United States	Tennessee Clinical Research Center	Nashville	Tennessee
United States	DermResearch New Braunfels	New Braunfels	Texas
United States	Virginia Clinical Research Inc.	Norfolk	Virginia
United States	Tory Sullivan, MD, PA	North Miami Beach	Florida
United States	Park Avenue Dermatology	Orange Park	Florida
United States	Skin Search of Rochester, Inc.	Rochester	New York
United States	Dermatology Research Center, Inc.	Salt Lake City	Utah
United States	Endeavor Clinical Trials, PA	San Antonio	Texas
United States	TCR Medical Corporation	San Diego	California
United States	University Clinical Trials, Inc.	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Sol-Gel Technologies, Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete cure at Day 29	The primary efficacy comparison between S2G6T-1 vs. rest of study arms will be based on the percentage of subjects at day 29 with complete cure of interdigital tinea pedis.mycological cure (i.e. negative dermatophyte culture and negative KOH) and clinical cure (i.e. absence of erythema, scaling and pruritus {scores of 0, each})	Day 29
Primary	Reduction in Tinea pedis SymptomS through treatment period.	comparison of Patient Assessment between S2G6T-1 vs. rest of study arms will be based on the percentage of subjects at day 8 with achieving decrease from baseline in the total score for pruritus and burning.	Day 8